<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03709719</url>
  </required_header>
  <id_info>
    <org_study_id>GRAALL-QUEST</org_study_id>
    <nct_id>NCT03709719</nct_id>
  </id_info>
  <brief_title>Blinatumomab in High-risk B-cell Precursor Acute Lymphoblastic Leukemia</brief_title>
  <acronym>GRAALL-QUEST</acronym>
  <official_title>A Phase II Study to Evaluate the Safety and the Efficacy of a Blinatumomab Based Consolidation and Maintenance in Patients With High-risk B-cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL). GRAALL-QUEST</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The GRAALL-QUEST study is a Phase 2 study nested in the GRAALL-2014/B study (NCT02617004).&#xD;
      The GRAALL-QUEST study evaluates the safety and the efficacy of blinatumomab-containing&#xD;
      consolidation and maintenance therapy in patients aged 18-59 years old with high-risk B-cell&#xD;
      precursor acute lymphoblastic leukemia (BCP-ALL) in first complete hematologic remission&#xD;
      after one induction course of standard chemotherapy and no central nervous system (CNS)&#xD;
      involvement at diagnosis.&#xD;
&#xD;
      High-risk patients are defined as patients with KMT2A/MLL gene rearrangement, and/or IKZF1&#xD;
      (Ikaros) intra-genic deletion and/or high post-induction Ig-TCR minimal residual disease&#xD;
      (MRD) level (≥10-4). In such patients not receiving blinatumomab, 3-year hematologic relapse&#xD;
      incidence and relapse-free survival (RFS) are estimated at 60-65% and 50% only, respectively,&#xD;
      on the basis of historical results.&#xD;
&#xD;
      A large subset of these high-risk patients (i.e. those with post-induction MRD level ≥10-3&#xD;
      and/or post-consolidation MRD level ≥10-4), but not all, will also be considered as&#xD;
      candidates for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in first&#xD;
      hematologic remission. The primary objective of the GRAALL-QUEST study is to evaluate the&#xD;
      efficacy of adding blinatumomab to consolidation and eventually maintenance therapy in term&#xD;
      of Relapse Free Survival (RFS). Secondary objectives are overall survival, comparison of RFS&#xD;
      and Overall Survival (OS) in transplanted versus non-transplanted patients, MRD response and&#xD;
      safety. Blinatumomab will be given as monthly cycles at the daily dose of 28 microg/d&#xD;
      continuous IV infusion, together with 3 triple intra-thecal (IT) chemotherapy injections. The&#xD;
      first cycle will start after completion of the first consolidation chemotherapy phase&#xD;
      (corresponding to the MRD2 time-point). Patients receiving allo-HSCT will receive successive&#xD;
      blinatumomab cycles until allo-HSCT. Patients not receiving allo-HSCT will receive a first&#xD;
      blinatumomab cycle (cycle 1) during the second consolidation chemotherapy phase, followed by&#xD;
      late intensification, then the third consolidation chemotherapy phase including another&#xD;
      blinatumomab cycle (cycle 2) and maintenance chemotherapy including three additional&#xD;
      blinatumomab cycles (cycles 3 to 5), for a total of 5 blinatumomab cycles maximum.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 20, 2018</start_date>
  <completion_date type="Anticipated">October 30, 2028</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2026</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Free Survival Y3</measure>
    <time_frame>3 years</time_frame>
    <description>Disease Free Survival at 3 years</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS Y3</measure>
    <time_frame>3 years</time_frame>
    <description>Overall survival at 3 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CIR Y3</measure>
    <time_frame>3 years</time_frame>
    <description>Cumulative incidence of relapse at 3 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NRM</measure>
    <time_frame>3 years</time_frame>
    <description>Non Relapse related Mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRD1</measure>
    <time_frame>after induction or on day 1 of first consolidation</time_frame>
    <description>Minimal Residual Disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRD2</measure>
    <time_frame>on day 1 of second consolidation</time_frame>
    <description>Minimal Residual Disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRD3</measure>
    <time_frame>on day 1 of late intensification(or at pre Allo-SCT evaluation)</time_frame>
    <description>Minimal Residual Disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRD4</measure>
    <time_frame>on day 1 of maintenance phase (or at day 100 after Allo-SCT)</time_frame>
    <description>Minimal Residual Disease</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">95</enrollment>
  <condition>Acute Lymphoblastic Leukemia, Adult B-Cell</condition>
  <arm_group>
    <arm_group_label>blinatumomab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Blinatumomab Injection</intervention_name>
    <description>Blinatumomab 28 μg/day : D1 to D28</description>
    <arm_group_label>blinatumomab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Included in GRAALL-2014/B&#xD;
&#xD;
               1. Whose blood and bone marrow explorations have been completed before the steroids&#xD;
                  prephase&#xD;
&#xD;
               2. Aged 18 to 59 years old with not previously treated B-lineage-ALL (including&#xD;
                  intrathecal injections) newly diagnosed according to the WHO 2008 definition with&#xD;
                  &gt; 20% bone marrow blasts&#xD;
&#xD;
               3. Whose karyotype shows no t(9;22) and/or the absence in molecular biology of&#xD;
                  BCR-ABL marker&#xD;
&#xD;
               4. With Eastern Cooperative Oncology Group (ECOG) performance status &lt; 3&#xD;
&#xD;
               5. With or without central nervous system (CNS) or testis involvement&#xD;
&#xD;
               6. Without other evolving cancer (except basal cell carcinoma of the skin or &quot;in&#xD;
                  situ&quot; carcinoma of the cervix) or its treatment should be finished at least since&#xD;
                  6 months&#xD;
&#xD;
               7. Having signed a written informed consent&#xD;
&#xD;
               8. With efficient contraception for women of childbearing age (excluding estrogens&#xD;
                  and IUS)&#xD;
&#xD;
               9. With health insurance coverage&#xD;
&#xD;
              10. Who have received or being receiving the steroid prephase&#xD;
&#xD;
          -  With High Risk (HR) B-ALL&#xD;
&#xD;
          -  ECOG ≤ 3&#xD;
&#xD;
          -  In Complete Remission after one or two induction cures and having received the three&#xD;
             blocks of consolidation N°1&#xD;
&#xD;
          -  With or without allogeneic donor&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  With ECOG status &gt; 3 after consolidation 1&#xD;
&#xD;
          -  With abnormal laboratory values as defined below after consolidation 1&#xD;
&#xD;
               1. Aspartate transaminase (AST) (SGOT) and/or alanine transaminase (ALT) (SGPT) ≥ 5&#xD;
                  x ULN&#xD;
&#xD;
               2. Total bilirubin ≥ 1.5 x ULN&#xD;
&#xD;
               3. Creatinine ≥ 1.5 x ULN or creatinine clearance &lt; 50 ml/min&#xD;
&#xD;
               4. Serum amylase and lipase ≥ 1.5 x ULN&#xD;
&#xD;
          -  With active uncontrolled infection, any other concurrent disease or medical condition&#xD;
             that is deemed to interfere with the conduct of the study as judged by the&#xD;
             investigator&#xD;
&#xD;
          -  New York Heart Association (NYHA) Functional Classification 3-4 cardiac disease&#xD;
&#xD;
          -  Infection with human immunodeficiency virus (HIV) or chronic infection with hepatitis&#xD;
             B virus (HBsAg positive) or hepatitis C virus (anti-HCV positive)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hopital saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 15, 2018</study_first_submitted>
  <study_first_submitted_qc>October 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2018</study_first_posted>
  <last_update_submitted>April 30, 2021</last_update_submitted>
  <last_update_submitted_qc>April 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blinatumomab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

